Trained autologous cytotoxic T-cells derived from PBMCs or splenocytes for immunotherapy of neuroblastoma
This study provides preliminary evidence supporting the efficacy of a personalized, PBMC-based immunotherapy for neuroblastoma. These findings highlight the potential for further development of this approach as a novel treatment strategy, paving the way for improved clinical outcomes in pediatric oncology.
Authors
- Alex I. Halpern (ORCID: https://orcid.org/0000-0003-4266-2291)
- Xiaofang Wu (ORCID: https://orcid.org/0000-0002-3782-7701)
- Mousumi Basu
- Mikael Petrosyan (ORCID: https://orcid.org/0000-0002-9928-5039)
- Anthony D. Sandler (ORCID: https://orcid.org/0000-0001-9440-2964)
- Douglas Shea (ORCID: https://orcid.org/0000-0003-2628-7831)
- Sarah Wright (ORCID: https://orcid.org/0000-0002-9539-3796)
- Marie Nelson
- Samuel Li
- Mark Yarmakovich
Institutions
- Children's National (US)
- George Washington University (US)
- New York University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1546441
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00